Sign in
GLTO Stock Price, Chart, Stats & News
Damora Therapeutics, Inc.
Save
34.47M
Market cap
–
Current P/E
–
Forward P/E
GLTO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.02% |
ROA | -80.54% |
ROE | -308.92% |
D/E | 0.00x |
Interest coverage ratio | – |
GLTO valuation
P/E | – |
P/S | – |
P/B | 0.17x |
P/CF | -6.03x |
P/FCF | -6.03x |
P/OCF | -6.03x |
PEG | -0.00x |
EV multiple | -8.17x |
About
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia.
Similar securities
Based on sector and market capitalization
Report issue